Fortrea Holdings Inc. logo FTRE - Fortrea Holdings Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 7
HOLD 4
SELL 1
STRONG
SELL 0
| PRICE TARGET: $21.33 DETAILS
HIGH: $25.00
LOW: $16.00
MEDIAN: $22.50
CONSENSUS: $21.33
DOWNSIDE: 5.16%

Stock News

3 Top Small-Cap Stocks With Market-Beating Momentum

3 Top Small-Cap Stocks With Market-Beating Momentum

Small-cap stocks have surrendered their lead over large caps in 2026 amid rising Treasury yields, but historical data shows small caps can rebound strongly when yields decline. Bank of America strategists see potential for a small-cap rebound if the 10-year Treasury yield peaks around their year-end forecast of 5%. I highlight three fundamentally strong small-cap stocks that have outperformed the market since the Russell 2000's recent high, defying the index's broader weakness.

Oct 15, 2026 09:10 AM • seekingalpha.com
MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE) Head to Head Contrast

MindWalk (NASDAQ:HYFT) & Fortrea (NASDAQ:FTRE) Head to Head Contrast

Fortrea (NASDAQ: FTRE - Get Free Report) and MindWalk (NASDAQ: HYFT - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Institutional and Insider Ownership 6.7% of MindWalk shares are

Oct 09, 2026 12:46 AM • defenseworld.net
Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

Oct 05, 2026 02:30 AM • globenewswire.com
Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets Adds dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network as Worldwide advances its strategy to scale clinical development, therapeutic leadership and high-growth markets

Sep 02, 2026 03:00 AM • globenewswire.com
Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue

Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue

Fortrea Holdings Inc. is rated Buy at ~$18.86, driven by an earnings turnaround from aggressive cost reductions, not revenue growth. Adjusted EBITDA rose ~24% in H1 despite a ~3.4% revenue decline, as direct costs and SG&A fell faster than sales. Net new business awards increased ~19% YoY, with a trailing-12-month book-to-bill ratio of 1.12x, but revenue conversion remains uncertain.

Aug 30, 2026 07:14 AM • seekingalpha.com

Price Targets